Equivalent Dose Conversion from Humalog to Novolog
Humalog (insulin lispro) 15 units three times daily converts directly to Novolog (insulin aspart) 15 units three times daily—these rapid-acting insulin analogues are clinically interchangeable on a unit-for-unit basis with no dose adjustment required. 1, 2
Rationale for 1:1 Conversion
The American Diabetes Association explicitly groups insulin lispro (Humalog), insulin aspart (Novolog), and insulin glulisine together as interchangeable options for prandial coverage, with the same rapid onset, peak action, and duration 1
Both insulin lispro and insulin aspart are rapid-acting insulin analogues that are absorbed rapidly from the subcutaneous injection site, resulting in better matching of insulin appearance with nutrient absorption compared to regular human insulin 3
Clinical trials demonstrate that insulin aspart provides similar glycemic control to insulin lispro when used in basal-bolus regimens, with comparable efficacy and safety profiles 2
Randomized controlled trials comparing biphasic insulin aspart 30 and biphasic insulin lispro 25 found noninferior glycemic control between the two formulations, with similar adverse-event profiles and hypoglycemia rates 4
Practical Implementation
Administer Novolog 15 units immediately before each meal (0-15 minutes prior), maintaining the same three-times-daily schedule used with Humalog 5
Continue the same basal insulin regimen without modification, as the conversion only affects the prandial component 1
Maintain metformin and other oral agents unless contraindicated 5
Monitoring Requirements
Check pre-meal and 2-hour postprandial glucose to confirm adequate prandial coverage after conversion 5
Monitor for hypoglycemia during the first week after switching, though the risk profile should remain unchanged 2
No adjustment to insulin-to-carbohydrate ratios or correction factors is needed, as both analogues have identical pharmacodynamic profiles 1
Common Pitfall to Avoid
Do not reduce the dose when converting between these rapid-acting analogues—they are bioequivalent and require identical dosing 1, 2
Avoid confusing this conversion with switching to regular human insulin, which would require administration 30 minutes before meals and dose adjustments due to longer duration of action 1